BTG, a specialist healthcare company, has launched its DigiFab product in the UK.
The product is used to treat patients enduring known or suspected life-threatening toxicity associated with heart conditions.
The launch will be conducted through the firm's international company, Protherics Medicines Development.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company's share price is up 53% over the past year, but fell 0.49% to 342.10p on the day of the announcement.
NR
